Navigation Links
Novel therapy improves immune function in teen with rare disease
Date:4/14/2011

In a novel approach that works around the gene defect in Wiskott-Aldrich syndrome, an inherited immune deficiency disorder, researchers used an alternative cell signaling pathway to significantly improve immune function in a 13-year-old boy with the disease. The study, at The Children's Hospital of Philadelphia, provides a proof-of-principle that immunotherapy, which harnesses elements of the body's immune system, may be used to treat this rare but often deadly disorder.

"If this encouraging initial result holds up in further clinical studies, we may have a new treatment option for patients with Wiskott-Aldrich syndrome," said pediatric immunologist Jordan S. Orange, M.D., Ph.D., who holds the newly established Jeffrey Modell Endowed Chair in Pediatric Immunology Research at Children's Hospital.

The immunotherapy study appears in the April 2011 issue of The Journal of Clinical Investigation.

Wiskott-Aldrich syndrome (WAS) is a complex immunodeficiency disorder characterized by recurrent infections, eczema and thrombocytopenia (a low platelet count). Mutations in the WAS gene disable its ability to produce WAS protein (WASp), which crucially affects immune cellsparticularly natural killer (NK) cells, a major component of the innate immune system. Without WASp, immune defenses are compromised, leaving WAS patients at risk for premature death from infection and cancers. This risk exists even for patients mildly affected by WAS.

The only current cure for WAS is stem cell transplantation, a potentially risky procedure presently justified in severe cases. In addition, Orange recently contributed to a small experimental study of gene therapy for WAS led by European researchers, which achieved clinical benefits in two severely affected young boys.

The current study represents a different approach from either stem cell transplantation or gene therapy. Instead of introducing normall
'/>"/>

Contact: John Ascenzi
ascenzi@email.chop.edu
267-426-6055
Children's Hospital of Philadelphia
Source:Eurekalert

Page: 1 2

Related biology news :

1. Data suggest liver experts should take care when prescribing novel antiviral HCV drugs
2. Novel method could improve the performance of proteins used therapeutically
3. Synthetic biology: TUM researchers develop novel kind of fluorescent protein
4. Team creates novel vaccine that produces strong immunity against cocaine high
5. Novel compounds show early promise in treatment of Parkinsons, Huntingtons, Alzheimers
6. GEN co-sponsors roundtable discussion on novel bioremediation techniques
7. In the lab, engineers novel liquid provides a solid fix for broken bones
8. Novel services for tropical forest monitoring with satellite
9. In new novel, secret discovery threatens company and damages love affair
10. Dow Agrosciences licenses exclusive novel crop enhancement technology
11. Novel regulatory process for T cells may help explain immune system diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2015)... , July 21, 2015  NXT-ID, Inc. (NASDAQ: ... biometric authentication company focused on the growing mobile ... wallet, announces that it has filed provisional patent ... Method. This invention highlights next ... authorizes an account, but also the user using ...
(Date:7/9/2015)... July 9, 2015  Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the fourth ... 2015 after the close of market. The company will ... at 2:00 p.m. PT (5:00 p.m. ET), during which ... participate on the live call, analysts and investors should ...
(Date:7/8/2015)... FRANKLIN LAKES , N.J. and NEW YORK ... and Company) and Guidepoint today announced ... selected start-up healthcare companies with free access to Guidepoint,s ... mentoring several start-ups that are developing cutting-edge technologies to ... of a dedicated Guidepoint research manager, each start-up entrepreneur ...
Breaking Biology News(10 mins):NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 2BD and Guidepoint Team to Connect Healthcare Start-up Companies With Business and Scientific Experts 3
... on the Cohen Y chromosome indicates the Jewish priesthood, the ... a single male lineage dating to ancient Hebrew times. ... Jewish priesthood that traced its patrilineal dynasty and seemed to ... (and brother of Moses), was one of a number of ...
... A scientist at the La Jolla Institute for Allergy & ... (NIH),s top awards -- the 2009 NIH Director,s Pioneer Award. ... costs of up to $4.7 million over five years, and ... whose novel proposals offer the potential to make extraordinary contributions ...
... RICHLAND, Wash. -- An analytical chemist at the Department ... with a National Institutes of Health Director,s New Innovator ... make new research and clinical diagnostic tools that are ... The award, which comes with a $1.5 million, ...
Cached Biology News:New genetic research indicates Jewish priesthood has multiple lineages 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 2Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 3Visionary concept earns La Jolla Institute scientist prestigious NIH Pioneer Award 4PNNL chemist earns NIH New Innovator Award 2PNNL chemist earns NIH New Innovator Award 3
(Date:7/28/2015)... YORK , July 28, 2015 Tauriga ... a diversified life sciences company, today announced that its ... shares of common stock of the Company from 1,000,000,000 ... on July 27, 2015 at the Law Offices of ...  At the Special Meeting, there were 480,655,929 shares of ...
(Date:7/28/2015)... , July 28, 2015  Moerae Matrix ... Phase 1 clinical trial with MMI-0100, a first-in-class ... being developed for pulmonary disorders characterized by inflammation ... United Kingdom , is a double-blind, ... evaluating the safety and tolerability of MMI-0100 when ...
(Date:7/28/2015)... , July 28, 2015 CSL ... Drug Administration has accepted for review the company,s Biologics ... VIII single-chain (rVIII-SingleChain) for the treatment of hemophilia A. ... endpoints. Hemophilia A is ... factor VIII; nearly all affected patients are male. People ...
(Date:7/28/2015)... Md. and RESEARCH TRIANGLE PARK, N.C., July 28, 2015 ... today announced its financial results for the second ...  sales grew nearly 300% as compared to the ... first launched," said Roger Jeffs, Ph.D., United Therapeutics, ... Orenitram sales was due to an increase in ...
Breaking Biology Technology:Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 2Tauriga Sciences, Inc. Stockholders Approve Increase In Authorized Common Stock 3Moerae Initiates Lipopolysaccharide (LPS) Challenge Study of Inhaled MMI-0100 for Pulmonary Disease Following Encouraging Safety and Tolerability Observed in Single Ascending Dose Phase 1 Study 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 2U.S. FDA Accepts for Review CSL Behring's Biologics License Application for Its Novel rVIII-SingleChain Therapy for Patients with Hemophilia A 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 2United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 3United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 4United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 5United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 6United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 7United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 8United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 9United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 10United Therapeutics Corporation Reports Second Quarter 2015 Financial Results 11
... , , ... AB (publ),and BioChromix AB announced today the formation of BioChromix Pharma ... its unique,knowledge of molecular chemistry. Karolinska Development will initially take,28 percent ... are very excited about BioChromix Pharma as they have a novel,approach ...
... , ... supports Higher Education and Local Youth by establishing Five College Scholarships. The first ... pursue Bio-Technology studies at NoVA. The company will also sponsor four scholarships for ... ...
... Jan. 13 Oxygen Biotherapeutics, Inc. (OTC Bulletin Board: ... the introduction of new products during a presentation today at the ... the brief presentation, limited by conference organizers to 10 minutes per ... in its cosmetics line during 2010. They include an eye cream ...
Cached Biology Technology:Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 2Karolinska Development Expands its Life Science Portfolio With BioChromix Pharma 3RiVIdium Inc. Creates Five Local Scholarships 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 2Oxygen Biotherapeutics, Inc. Outlines Plans for New Products During Investor Conference Presentation 3
Glycerokinase; from Bacillus stearothermophilus...
...
...
... safety cabinets Heraeus HERAsafe KS convince with an ... ,The new frameless slanted window does not obscure ... front window design makes it easy to work ... with a height of more than 250 mm ...
Biology Products: